Resilience as a resource in coping with Cystic Fibrosis has received scientific attention over the last years and empirical results have been accumulating and promising. Therefore, the Mental Health Working Group of the ECFS has advocated the inclusion of resilience into routine assessment as an addition to the assessment of anxiety and depression. The Brief Resilience Scale (BRS) was proposed as an economical supplement which is both brief and well researched. The objective of this study was to investigate the usefulness of the scale as routine assessment. The Cystic Fibrosis Centre in Innsbruck is an ISO certified facility with a multidisciplinary care team who accompany CF patients continuously at quarterly medical check-ups (111 adults are eligible). Once a year, in a psychological check-up, anxiety (GAD7) and depression (PHQ9) as well as quality of life (CFQ-R) are routinely assessed. In addition, a longitudinal study on resilience is under way and the BRS was newly included during the routine check-up in February 2021. Associations with non-routine study instruments (PANAS – Positive and Negative Affectivity) have also been analyzed. 75 adult patients attending the check-up in 2021 could be analyzed. Multiple regressions with BRS as predictor (and controlling for lung function and BMI) resulted in significant explained variance for depression (R2 = .292), positive (R2 = .303) and negative affectivity (R2 = .309) and anxiety (R2 = .182). BRS-Scores were significantly associated only with two out of twelve CFQ-R-Scores (psychological well-being, health perception). The BRS is a well-researched assessment tool. However, predictive power is substantial only in parts of relevant variables. Therefore, it is necessary to further evaluate the clinical utility of the scale, in particular, as other resilience instruments used in our longitudinal resilience study have already shown strong predictive power in several of our past analyses (e.g. Mitmansgruber et al., 2021).

Objectives: Elexacaftor/Tezacaftor/Ivacaftor (ETI) improves outcome in patients with cystic fibrosis. To evaluate possible effects of ETI specifically on Pseudomonas aeruginosa (PA) we assessed sputum cultures and PA antibodies in people with CF (PwCF). Methods: At the CF Centre Innsbruck, PwCF had routine evaluation of serum PA antibodies and sputum analysis before and during ETI. Induced sputum was collected during in-house physiotherapy. Results from sputum cultures and PA antibody status (Alkaline Protease, anti-Pseudomonas Elastase, Anti-Exotoxin A, PA Immunoglobulin G) were analysed in the local lab. PwCF with at least four sputum cultures one year before and in the first year of ETI were included. Leeds criteria were used to determine chronic, intermittent or no PA infection. PwCF with at least one PA antibody result above cut off (1:500; 2.95 EU) were counted positive. Basic therapy was not changed. Results: Of 55 PwCF starting ETI, 30 (24 female) were included. Reasons for exclusion were treatment started at another centre (8 PwCF), treatment duration of less than 4 months (9 PwCF), and low number of sputum culture results (8 PwCF) respectively. At ETI initiation, PwCF (mean age 24.6, 9–39) mostly had a moderate lung disease with mean FEV1 61.7% (18.7–108.3%) and mean Bhalla CT score of 13.8 (5–25). This preliminary data shows, that 32.8% of all sputum samples before ETI (n = 299; mean 10.0 per PwCF) were PA positive, and 32.7% of sputum cultures during ETI (n = 226; mean 7.5 per PwCF) remained PA positive. Chronic PA infection was detected in 9 before and 8 PwCF during ETI. Intermittent PA infection was detected in 8 before and 5 PwCF during ETI (4 and 3 PA antibody positive). 13 before and 17 PwCF (3 and 4 PA antibody positive) during ETI had no PA positive culture. Conclusions: Our preliminary results suggest that particularly PwCF with structural lung damage and chronic PA infection remain chronically PA culture and PA antibody positive during one year ETI.

Table 1.CGM Brompton Criteria.Diagnostic Category CGM Values Management CFRD 2 × peaks >11.1 mmol/L and >10% of time >7.8 mmol/L Start insulin Impaired glucose tolerance No more than 1 peak >11.1 mmol/l and/or >10% of time >7.8 mmol/l Consider insulin Repeat Freestyle Libre in 6 months Indeterminate glucose homeostasis 4.5-10% of time >7.8 mmol/L or hypoglycaemia Close monitoring Dietary modification for hypoglycaemia/ hyperglycaemia Repeat Freestyle Libre in 12 months.Normal No peaks >11.1 mmol/L and <4.5% of time >7.8 mmol/L No intervention required Repeat Freestyle Libre when indicated